Dr. Barry B. Bercu 1944-2023 Barry B. Bercu, M.D. died on Friday, November 24, 2023. Dr. Bercu, a pediatric endocrinologist…
Read MoreMore Articles
Dear PES members and friends, With the advancing fall, our recent elections led to an outstanding slate of new leaders for next year. Congratulations to Laurie Cohen, Andrew Dauber, and…
Read More
Medication Shortage Alert – Pamidronate Disodium Injection: Anna Ryabets-Lienhard, DO, Drugs and Therapeutics Committee Update 10/25/23: As of August-September, there has been a national shortage of pamidronate IV injection. The…
Read More
Novo Nordisk announced on 11/8/2023 that their long-acting insulin, Levemir®, will be phased out from United States markers completely discontinuing by December 2024. It cited manufacturing constraints, reduced patient access and…
Read More
Jade Wyatt, MD I am currently a third-year pediatric endocrinology fellow at the University of North Carolina. I grew up in Texas, attended medical school at the University of Oklahoma,…
Read More
The Somatomedin and Dual Effector Theories of Growth Hormone Action Submitted by Alan D. Rogol, M.D., Ph.D. The somatomedin hypothesis stated that the uptake of sulfate in, for example rat…
Read More
New Drugs and Therapeutics Update – NGENLA By Dania Al-Hamad, MD, and Christine Yu, MD NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog, was approved by the FDA in…
Read More
Dear PES members and friends, It has been an intense early fall, on several fronts. In early October we participated in the very successful international “Endo Bridge 2023” conference in…
Read More
Historical Tidbit: Robert T. Morris (1857-1945) and Human Ovarian Transplantation Submitted by Alan D. Rogol, M.D., Ph.D. Robert Morris was an exceptional surgeon in New York City. He was among…
Read More
Patricia Chu, MD I am a fourth-year Combined Adult and Pediatric Endocrinology Fellow at Penn Medicine/Children’s Hospital of Philadelphia and am currently in the Master of Science in Clinical Epidemiology (MSCE)…
Read More
Brief Therapeutic Update from PES Drugs and Therapeutics Committee Jardiance® (empagliflozin) and Synjardy® (empagliflozin and metformin hydrochlorothiazide) Jardiance® (empagliflozin) and Synjardy® (empagliflozin and metformin hydrochlorothiazide) were approved by the…
Read More